Literature DB >> 3921277

Long-term results, hemodynamics, and complications after combined heart and lung transplantation.

K D Dawkins, S W Jamieson, S A Hunt, J C Baldwin, C M Burke, A Morris, M E Billingham, J Theodore, P E Oyer, E B Stinson.   

Abstract

During the first 31/2 years of the Stanford heart-lung transplant program, 23 transplants have been carried out in 22 patients with severe pulmonary vascular disease. Actuarial survival curves predict 1 and 2 year survival rates of 71% and 57%, respectively, for all patients. As a result of increasing experience, the early mortality of 26% has been reduced, with only one early death occurring in the last eight patients; prior cardiac surgery was a contributing factor in three of the six patients suffering early deaths. Two late deaths occurred in the series 14 and 15 months after operation. One patient died suddenly as a result of an acute myocardial infarct and the other patient died because of respiratory failure. At autopsy, both patients had severe proliferative coronary atherosclerosis with obliterative bronchiolitis affecting the lungs. An additional patient required a retransplant for obliterative bronchiolitis 37 months after the initial procedure, and he too was found to have severe coronary artery disease. Hemodynamics and left ventricular function were normal in patients studied 1 and 2 years after undergoing the transplantation procedure. Thus, the early mortality and morbidity of combined heart and lung transplantation has been significantly reduced, but the long-term complications, particularly graft atherosclerosis and obliterative bronchiolitis, are yet to be fully controlled.

Entities:  

Mesh:

Year:  1985        PMID: 3921277     DOI: 10.1161/01.cir.71.5.919

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Intensive care management of children following heart and heart-lung transplantation.

Authors:  B Whitehead; I James; P Helms; J P Scott; R Smyth; T W Higenbottam; J McGoldrick; T A English; J Wallwork; M Elliott
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Single lung transplantation and pulmonary hypertension.

Authors:  T Higenbottam
Journal:  Br Heart J       Date:  1992-02

Review 3.  Heart-lung transplantation: current indications, prognosis and specific considerations.

Authors:  Jérôme Le Pavec; Sébastien Hascoët; Elie Fadel
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

4.  Bilateral sequential lung transplantation for end stage septic lung disease.

Authors:  A Hasan; P A Corris; M Healy; N Wrightson; A D Gascoigne; D A Waller; I Wilson; C J Hilton; F K Gould; J Forty
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 5.  State of the Art of Combined Heart-Lung Transplantation for Advanced Cardiac and Pulmonary Dysfunction.

Authors:  Jay J Idrees; Gösta B Pettersson
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

6.  Diastolic function after cardiac and heart-lung transplantation.

Authors:  G Hausdorf; N R Banner; A Mitchell; A Khaghani; M Martin; M Yacoub
Journal:  Br Heart J       Date:  1989-08

7.  Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants.

Authors:  A R Penketh; T W Higenbottam; J Hutter; C Coutts; S Stewart; J Wallwork
Journal:  Thorax       Date:  1988-10       Impact factor: 9.139

8.  Anesthetic management of heart and lung transplantation: analysis of 14 cases in a single center.

Authors:  Jian Fang; Xiaoxue Zhuang; Zhaomin Huang; Lan Lan; Hanyu Yang; Chao Yang; Shaobo Xie
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 3.005

9.  Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

Authors:  T Higenbottam; A Y Butt; A McMahon; R Westerbeck; L Sharples
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

Review 10.  Bronchiolitis obliterans.

Authors:  T E King
Journal:  Lung       Date:  1989       Impact factor: 2.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.